Experimental cancer drug may boost Covid immune response, study finds
Researchers say the antiviral triggers ‘highly effective’ immune response to string of respiratory diseases
An experimental cancer drug derived from a poisonous plant could be used to boost the body’s natural immune response to Covid-19, new research suggests.
The antiviral, called thapsigargin, is being trialled as a treatment for prostate cancer patients. But scientists at the University of Nottingham believe the drug, derived from a Mediterranean weed that is highly toxic to sheep and cattle, may also be used to fight the coronavirus.
In what the team describe as a “ground-breaking study”, small doses of the antiviral were found to trigger a “highly effective” immune response against three types of human respiratory viruses including Sars-CoV-2, which causes Covid.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Study leader Professor Kin-Chow Chang said that the “hugely significant” findings “strongly indicate” that “thapsigargin and its derivatives are promising antiviral treatments against Covid and influenza” - and also “have the potential to defend us against the next Disease X pandemic”.
“A new generation of antivirals, such as thapsigargin, could play a key role in the control and treatment of important viral infections in both humans and animals,” he added.
Chang admits that more testing is “clearly needed”, with the Daily Mail noting that “no evidence exists that it will work on humans”.
However, the research conducted so far has found that thapsigargin is “effective at blocking symptoms when used before or during active infection in petri dish tests and on mice”, the newspaper reports.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Chas Newkey-Burden has been part of The Week Digital team for more than a decade and a journalist for 25 years, starting out on the irreverent football weekly 90 Minutes, before moving to lifestyle magazines Loaded and Attitude. He was a columnist for The Big Issue and landed a world exclusive with David Beckham that became the weekly magazine’s bestselling issue. He now writes regularly for The Guardian, The Telegraph, The Independent, Metro, FourFourTwo and the i new site. He is also the author of a number of non-fiction books.
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published
-
Mpox: how dangerous is new health emergency?
Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
By The Week UK Published
-
What is POTS and why is it more common now?
The explainer The condition affecting young women
By Devika Rao, The Week US Published
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK Published
-
Should masks be here to stay?
Talking Points New York Governor Kathy Hochul proposed a mask ban. Here's why she wants one — and why it may not make sense.
By Anya Jaremko-Greenwold, The Week US Published
-
Covid might be to blame for an uptick in rare cancers
The explainer The virus may be making us more susceptible to certain cancers
By Devika Rao, The Week US Published
-
Long Covid and chronic pain: is it all in the mind?
The Explainer 'Retraining the brain' could offer a solution for some long Covid sufferers
By The Week UK Published